AMBER LAMUS: Open Payments
NPI 1184084568 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$553 in 46 payments from 6 companies in 2025. Trend: 2023 $315 · 2024 $213 · 2025 $553
Food & beverage: $553
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $229 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Neurocrine BioSciences, Inc. | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
Products named: VRAYLAR, INGREZZA, ABILIFY MAINTENA, CAPLYTA, REXULTI, INVEGA SUSTENNA, UZEDY.
Industry payments across OH — which companies pay providers there.
